PALVELLA THERAPEUTICS, INC. (PVLA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6979471090
PALVELLA THERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -38.60 m USD |
| EBIT | -41.72 m USD |
| Net income | -41.72 m USD |
| Diluted EPS – continuing operations | -3.71 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PALVELLA THERAPEUTICS, INC.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
More stocks
- Alps Alpine Co Ltd (6770.T)
- ADMA BIOLOGICS, INC. (ADMA)
- Pacific Basin Shipping Ltd (2343.HK)
- LiveRamp Holdings, Inc. (RAMP)
- Dermapharm Holding (DMP.DE)
- Elekta AB (publ) (EKTA B.ST)
- PENN Entertainment, Inc. (PENN)
- PagSeguro Digital Ltd (PAGS)
- Jonjee Hi-tech Industrial and Commercial Holding Co Ltd (600872.SS)
- POSCO ICT Co. Ltd. (022100.KS)
- DUCOMMUN INC /DE/ (DCO)
- Ballys Intralot S.A. (BYLOT.AT)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.